

## **Theravance Biopharma to Host Investor and Analyst Day on December 12th**

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/20/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY. Management will present updates regarding the post-split business outlook, commercial strategy for VIBATIV<sup>®</sup>, and key development programs. Presentations will begin at 9:00 am EST.

For additional information and registration, please e-mail [TBPHinvestorday@theravance.com](mailto:TBPHinvestorday@theravance.com), or call 443-213-0506.

The presentation will be webcast live and can be reached by visiting the Investor Relations section of Theravance Biopharma's website at [www.theravance.com](http://www.theravance.com), under the Presentations & Events tab. The event will be archived on the Company's web site for 90 days.

### **About Theravance Biopharma**

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, central nervous system (CNS)/pain, and gastrointestinal (GI) motility dysfunction.

Theravance Biopharma has one approved product, VIBATIV<sup>®</sup> (telavancin), which was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, the Company has an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) (FF/UMEC/VI), the combination of the bifunctional muscarinic antagonist-beta2 agonist (MABA) GSK961081 ('081) and FF ('081/FF), and MABA monotherapy. By leveraging its proprietary insight of multivalency to drug discovery, the Company is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Theravance Biopharma is a publicly-held corporation, with U.S. headquarters located in South San Francisco, California, and trades on the NASDAQ Global Select Market under the symbol TBPH. For additional information, please visit [www.theravance.com](http://www.theravance.com).

THERAVANCE, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE and VIBATIV are trademarks and/or registered trademarks of the Theravance Biopharma group of companies.

### **Contact Information:**

Rick E Winningham  
Chief Executive Officer  
650-808-4045  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

Source: Theravance Biopharma

News Provided by Acquire Media